Foghorn Therapeutics (FHTX) Profit After Tax (QoQ) (2019 - 2026)
Foghorn Therapeutics (FHTX) Profit After Tax (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Foghorn Therapeutics | 362.65 Mn | 273.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.61% |
| Dec 31, 2025 | -31,986.76% |
| Sep 30, 2025 | 100.38% |
| Jun 30, 2025 | 4.60% |
| Mar 31, 2025 | 9.04% |
| Dec 31, 2024 | -12.19% |
| Sep 30, 2024 | 19.82% |
| Jun 30, 2024 | 8.14% |
| Mar 31, 2024 | -133.18% |
| Dec 31, 2023 | 625.53% |
| Sep 30, 2023 | 51.35% |
| Jun 30, 2023 | 3.28% |
| Mar 31, 2023 | -137.70% |
| Dec 31, 2022 | 4,928.30% |
| Sep 30, 2022 | 93.87% |
| Jun 30, 2022 | -1.48% |
| Mar 31, 2022 | 7.63% |
| Dec 31, 2021 | -11.72% |
| Sep 30, 2021 | -12.85% |
| Jun 30, 2021 | -0.54% |